Replies to post #629059 on NorthWest Biotherapeutics Inc (NWBO)

[maverick_1]

HOW A very small minority truly understand what will UNFOLD:

The IMPORTANCE of receiving finalization on A serious discussion(S) in NEW TRIAL(S)
far, far overwhelms that of a PROCEDURAL UK MAA as evidenced by grand standing sticky I am NOT raving about:

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=172724432

was a U TURN that was clearly EVIDENT since:
1)NOV 2022 JAMA ONCOLGY &
2)LEAPFROGGED by June 2023 ASCO
3) Aug 3 MERCK stated NEW LANDSCAPE
4) NWBO 2Q 10Q: “in some serious discussions on new trials”!

OBVIOUSLY NWBO needed it’s 4th FRESH BLOOD INFUSION Vs TIRED from pocket being
EMPTIED BY DEEP POWERFUL DARK FORCES

Too few still lack DISCERNMENT seen since 2014: STILL NEOPHYTICALLY GULLIBLE & NAIVE.

WOULDN’T ONE WANT THE BOATLOAD of New TrialS
And what that brings!

VikingInvest
Re: None
Thursday, September 07, 2023 12:56:23 PM
Post# of 629068
I think it is interesting that posters are so focused on the value associated with submission and approval. The real move will be if they sign a partnership agreement with a BP that, if exclusive for certain cancer indications, will likely have a decent upfront payment and milestone payments. Then you can throw all the submission and approval predictions out the window. Where we will land will be determined on the agreement and it's content, which currently is impossible to predict.

BTW MISGUIDED Entertainers bring NO lasting VALUE:

Except what has been amply demoed since 2014! LACK OF EXPERIENCE: only able to deal with the perfunctory NONE! of which applied to NWBO
FUMBLING Devastation on $$$ & on EVERY COUNT way AND beyond siding with DISGRACED by being tantalized by Neil Woodford is emblematic of what still pervades:

Can NOT teach an OLD DOG any tricks.

RAMPANTLY PATHETIC even at these final stages in this EPIC.

BTW NWBO turnaround on Tuesday was achieved on Twitter vs here!

We got a handful of high profile tweeterS dealing on many fronts & trading platforms! not evident on iHub which are ignored with iHubbers dealing with picayune: Time is $
AND I CAN AMPLY DOCUMENT vs here say 100% residing on iHub since 2014: Talk is cheap. ONLY MONEY does the talking!

vs the incessant unproductive exchanges on iHUB since at least Spring 2023.
dealings with Fudders.

DIFFERENT STROKES for DIFFERENT FOLKS

[ilovetech]

dstock - Editi: "did" understand you. Typing on a phone 😏

[biosectinvestor]

Roche is a huge company with lots of different revenue streams, and commercial drugs. Of course it might not make a difference in THAT case and for what drug? For heaven’s sake, that is a ridiculous comparison.

This is a broad cancer vaccine, the MHRA is a well respected regulator, and this has been discounted as a “failed drug” due to short fud. Approval by MHRA foreshadows the future for this drug is likely positive ahead in many other jurisdictions AND impacts on sustainable revenues for a company with a very low burn rate already.